Asgharzadeh S, Marachelian A, Villablanca JG, Liu WY, Kennedy R, Sposto R, Naranjo A, Tenney S, Yu AL, Ozkaynak MF, Sondel PM, Park JR, Seeger RC. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy. Pediatr Blood Cancer. 2022 Sep;69(9):e29719. doi: 10.1002/pbc.29719. Epub 2022 Apr 20. PubMed PMID: 35441784; PubMed Central PMCID: PMC9329214.
Study ID Citation
Abstract
Minimal disease quantification may predict Event-Free (EFS) and Overall Survival (OS). We evaluated mRNA expression of five neuroblastoma-associated genes (NB5 assay) in bone marrows (BM) of patients with newly diagnosed high-risk neuroblastoma who received consistent immunotherapy. mRNA expression of CHGA, DCX, DDC, PHOX2B, and TH genes in BM of 479 patients enrolled on immunotherapy arm of Children’s Oncology Group trials ANBL0032 and ANBL0931 was evaluated using real-time polymerase chain reaction (PCR) based TaqMan Low-Density Array. Results from End-Consolidation and End-Therapy were analyzed for association with 5-year EFS/OS, and patient and tumor characteristics. Tests of statistical significance were two-sided.